Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BMRN > SEC Filings for BMRN > Form 8-K on 10-Jun-2014All Recent SEC Filings

Show all filings for BIOMARIN PHARMACEUTICAL INC

Form 8-K for BIOMARIN PHARMACEUTICAL INC


10-Jun-2014

Change in Directors or Principal Officers, Submission of Matters to a


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendments to 2006 Employee Stock Purchase Plan

On June 4, 2014, at the 2014 Annual Meeting of the Stockholders (the "Annual Meeting") of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company"), BioMarin's stockholders approved amendments to the Company's Amended and Restated 2006 Employee Stock Purchase Plan (the "2006 ESPP") to: (i) increase the aggregate number of shares of the Company's common stock, par value $0.001 per share ("Common Stock"), authorized for issuance under the 2006 ESPP from 2,500,000 to 3,500,000 shares; and (ii) extend the term of the 2006 ESPP to May 2, 2018.

The amendments to the 2006 ESPP had been previously approved, subject to stockholder approval, by the Board of Directors of BioMarin. The amendments to the 2006 ESPP became effective immediately upon stockholder approval at the Annual Meeting.

A summary of the material terms of the 2006 ESPP is set forth in BioMarin's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 22, 2014 (the "Proxy Statement"). That summary and the foregoing description are qualified in their entirety by reference to the text of the 2006 ESPP, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.



Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 4, 2014, BioMarin held the Annual Meeting at the Cavallo Point Lodge, 601 Murray Circle, Fort Baker, Sausalito, CA. A total of 145,898,520 shares of Common Stock were entitled to vote as of April 7, 2014, the record date for the Annual Meeting. There were 133,214,373 shares of Common Stock present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on four (4) proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal 1. Election of Directors



                                                                           Broker
      Directors Elected                 Vote For          Withheld        Non-Votes
      Jean-Jacques Bienaimé             120,238,424        4,749,465       8,226,484
      Kenneth M. Bate                   115,276,379        9,711,510       8,226,484
      Michael Grey                      124,506,772          481,117       8,226,484
      Elaine J Heron, Ph.D.             124,108,548          879,341       8,226,484
      Pierre Lapalme                    123,171,342        1,816,547       8,226,484
      V. Bryan Lawlis, Ph.D.            124,470,524          517,365       8,226,484
      Richard A. Meier                  124,509,924          477,965       8,226,484
      Alan J. Lewis                     112,687,917       12,299,972       8,226,484
      Dennis J. Slamon, M.D., Ph.D.     124,688,185          299,704       8,226,484
      William D. Young                  122,668,651        2,319,238       8,226,484

Based on the votes set forth above, each of the ten nominees set forth above was duly elected to serve as a director of BioMarin for a one year term, or until his or her respective successor has been duly elected and qualified at the next annual meeting of stockholders of BioMarin.


Proposal 2. Vote on the Amendments to the 2006 Employee Stock Purchase Plan

The vote to approve amendments to the 2006 ESPP, as set forth in the Proxy
Statement, received the following votes:



                                                              Broker
                  For            Against       Abstain       Non-Votes
                  124,272,924     521,620       193,345       8,226,484

Based on the votes set forth above, the amendments to the 2006 ESPP, as set forth in the Proxy Statement, were approved by the stockholders.

Proposal 3. Advisory Vote on the Compensation of the Company's Named Executive
Officers

The advisory (non-binding) vote to approve the compensation of BioMarin's named
executive officers, as set forth in the Proxy Statement, received the following
votes:



                                                                Broker
                 For             Against         Abstain       Non-Votes
                 110,051,643     14,725,509       210,737       8,226,484

Based on the votes set forth above, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, was approved in an advisory vote by the stockholders.

Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2014 received the following votes:

For Against Abstain 132,345,005 657,499 211,869

Based on the votes set forth above, the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2014 was duly ratified by the stockholders.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Number         Description

10.1     †     BioMarin Pharmaceutical Inc. Amended and Restated 2006 Employee Stock
               Plan, as adopted on June 21, 2006 and as amended on March 5, 2014.

† Management contract or compensatory plan or arrangement.


  Add BMRN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BMRN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.